HES
MCID: HYP098
MIFTS: 65

Hypereosinophilic Syndrome (HES)

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hypereosinophilic Syndrome

MalaCards integrated aliases for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 12 76 53 37 55 15 73
Eosinophilia 12 76 29 55 44 15 73
Hes 53 48
Disseminated Eosinophilic Collagen Disease 73
Hypereosinophilic Syndrome, Idiopathic 53
Idiopathic Hypereosinophilic Syndrome 73
Eosinophilic Leukocytosis 12
Eosinophilic Disorder 73

Classifications:



External Ids:

Disease Ontology 12 DOID:999
ICD10 33 D72.1
ICD9CM 35 288.3
MeSH 44 D004802
SNOMED-CT 68 27955006
KEGG 37 H01599

Summaries for Hypereosinophilic Syndrome

NIH Rare Diseases : 53 Hypereosinophilic syndrome (HES) refers to a rare group of conditions that are associated with persistent eosinophilia with evidence of organ involvement. Signs and symptoms vary significantly based on which parts of the body are affected. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected. The condition was originally thought to be "idiopathic" or of unknown cause. However, recent advances in diagnostic testing have allowed a cause to be identified in approximately a quarter of cases. Management varies based on the severity of the condition and whether or not an underlying cause has been identified but generally includes imatinib or corticosteroids as an initial treatment.

MalaCards based summary : Hypereosinophilic Syndrome, also known as eosinophilia, is related to primary hypereosinophilic syndrome and hypereosinophilic syndrome, idiopathic, and has symptoms including nausea and vomiting, constipation and angina pectoris. An important gene associated with Hypereosinophilic Syndrome is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5.0�?108/l... more...

Related Diseases for Hypereosinophilic Syndrome

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 791)
# Related Disease Score Top Affiliating Genes
1 primary hypereosinophilic syndrome 33.8 FGFR1 FIP1L1 PDGFRA PDGFRB
2 hypereosinophilic syndrome, idiopathic 33.8 FIP1L1 IL3 IL5 KIT PDGFRA PDGFRB
3 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 33.6 FGFR1 PDGFRA PDGFRB
4 chronic eosinophilic pneumonia 32.8 CCL11 IL5 RNASE3
5 omenn syndrome 32.6 IGHE IL4 IL5
6 endomyocardial fibrosis 32.4 FIP1L1 IL4 PDGFRA
7 eosinophilic pneumonia 31.9 CCL11 CCL17 CSF2 IL13 IL3 IL5
8 intestinal schistosomiasis 31.2 IL13 IL4 IL5
9 chronic eosinophilic leukemia 31.2 ABL1 FGFR1 FIP1L1 IFNA1 KIT PDGFRA
10 paragonimiasis 31.2 CCL17 IL13 IL5 RNASE3
11 pulmonary eosinophilia 30.9 CCL11 CCL17 EPX IL13 IL4 IL5
12 eosinophilic colitis 30.6 PRG2 RNASE3
13 churg-strauss syndrome 30.3 CCL17 IL5 RNASE3
14 bronchitis 30.3 CCL11 IL5 RNASE3
15 wells syndrome 30.3 IL2RA IL5 RNASE3
16 toxic oil syndrome 30.2 IGHE IL2RA IL4 IL5
17 eosinophilic gastroenteritis 30.2 CCL11 EPX IL3 IL5 RNASE3
18 eosinophilic granuloma 30.2 EPX RNASE3
19 gastroenteritis 30.1 CCL11 IFNA1 IL4 IL5 RNASE3
20 systemic mastocytosis 30.1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
21 loeffler endocarditis 30.1 FIP1L1 IL5 PDGFRA RNASE3
22 strongyloidiasis 30.0 CCL11 IL13 IL5
23 mastocytosis 29.9 FIP1L1 IL13 IL2RA KIT PDGFRA PDGFRB
24 kimura disease 29.8 CCL11 IL4 IL5 RNASE3
25 myeloproliferative neoplasm 29.8 ABL1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
26 bullous pemphigoid 29.8 CCL11 IL5 RNASE3
27 leiomyosarcoma 29.7 KIT PDGFRA PDGFRB
28 allergic bronchopulmonary aspergillosis 29.7 CCL17 EPX IL4 IL5
29 pdgfra-associated chronic eosinophilic leukemia 29.7 FIP1L1 PDGFRA
30 chronic myelomonocytic leukemia 29.7 CSF2 KIT PDGFRB
31 milk allergy 29.6 IL4 IL5 RNASE3
32 aspergillosis 29.6 CCL17 CSF2 IL4 IL5
33 pemphigoid gestationis 29.6 CCL11 IL5
34 mycosis fungoides 29.6 CCL17 IFNA1 IL2RA IL5
35 desmoid tumor 29.6 KIT PDGFRA PDGFRB
36 dermatofibrosarcoma protuberans 29.5 KIT PDGFRA PDGFRB
37 esophagitis, eosinophilic, 1 29.5 CCL11 IL13 IL5
38 rhinitis 29.5 CCL11 EPX IGHE IL13 IL4 IL5
39 esophagitis 29.5 CCL11 IL13 IL5
40 8p11 myeloproliferative syndrome 29.5 FGFR1 KIT PDGFRB
41 folliculitis 29.5 CCL11 IL2RA IL4 IL5
42 acquired immunodeficiency syndrome 29.5 CSF2 IFNA1 IL2RA
43 cough variant asthma 29.4 IL4 IL5 RNASE3
44 cutaneous t cell lymphoma 29.4 CCL17 IFNA1 IL2RA IL4
45 polycythemia vera 29.4 ABL1 IFNA1 IL3 KIT PDGFRA PDGFRB
46 inflammatory bowel disease 29.4 CCL11 EPX IL13 IL4 IL5
47 myeloid leukemia 29.4 ABL1 CSF2 IL3 KIT
48 stevens-johnson syndrome/toxic epidermal necrolysis 29.4 CCL17 IL13 IL5
49 gastrointestinal stromal tumor 29.3 ABL1 KIT PDGFRA PDGFRB
50 pollen allergy 29.3 EPX IL13 IL3 IL5 RNASE3

Comorbidity relations with Hypereosinophilic Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Deficiency Anemia Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to Hypereosinophilic Syndrome

Symptoms & Phenotypes for Hypereosinophilic Syndrome

UMLS symptoms related to Hypereosinophilic Syndrome:


nausea and vomiting, constipation, angina pectoris, abdominal pain, edema, pruritus, myalgia, chest pain, diarrhea, snoring, coughing, icterus, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.68 PDGFRA
2 Decreased viability GR00221-A-1 9.68 ABL1 FGFR1 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 9.68 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.68 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 9.68 PDGFRA PDGFRB
6 Decreased viability GR00301-A 9.68 KIT
7 Decreased viability GR00342-S-1 9.68 ABL1 PDGFRB
8 Decreased viability GR00342-S-2 9.68 ABL1
9 Decreased viability GR00342-S-3 9.68 ABL1
10 Decreased viability GR00402-S-2 9.68 ABL1 FGFR1 KIT PDGFRA PDGFRB
11 Decreased substrate adherent cell growth GR00193-A-1 9.43 KIT
12 Decreased substrate adherent cell growth GR00193-A-2 9.43 ABL1 KIT
13 Decreased substrate adherent cell growth GR00193-A-4 9.43 ABL1 FGFR1 KIT

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 ABL1 CCL11 CCL17 CSF2 EPX FGFR1
2 digestive/alimentary MP:0005381 9.97 ABL1 FGFR1 IL13 IL2RA IL4 IL5
3 craniofacial MP:0005382 9.91 ABL1 CSF2 FGFR1 IL4 KIT PDGFRA
4 endocrine/exocrine gland MP:0005379 9.91 ABL1 CSF2 FGFR1 IL13 IL2RA IL4
5 immune system MP:0005387 9.8 ABL1 CCL11 CCL17 CSF2 EPX FGFR1
6 respiratory system MP:0005388 9.32 ABL1 CCL11 CSF2 IL13 IL2RA IL4

Drugs & Therapeutics for Hypereosinophilic Syndrome

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
6
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
7 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
8 Neurotransmitter Agents Phase 4,Phase 2
9 Adrenergic beta-Agonists Phase 4,Phase 2
10 Adrenergic Agonists Phase 4,Phase 2
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Adrenergic Agents Phase 4,Phase 2
13 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3
14 Anti-Allergic Agents Phase 4,Phase 2
15 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
16 Respiratory System Agents Phase 4,Phase 3,Phase 2
17 Tocolytic Agents Phase 4,Phase 2
18 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
19 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Bronchodilator Agents Phase 4,Phase 2
21 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
22 Autonomic Agents Phase 4,Phase 3,Phase 2
23 Albuterol Phase 4,Phase 2
24 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
25 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
27 Hormone Antagonists Phase 4,Phase 2,Phase 3
28 Hormones Phase 4,Phase 2,Phase 3
29 Methylprednisolone acetate Phase 4,Phase 3
30 Prednisolone acetate Phase 4,Phase 3
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
32 Antiemetics Phase 4,Phase 3,Phase 2
33 glucocorticoids Phase 4,Phase 2,Phase 3
34 Neuroprotective Agents Phase 4,Phase 3
35 Protective Agents Phase 4,Phase 3,Phase 2
36
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
37
Thioguanine Approved Phase 3 154-42-7 2723601
38
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
39
Daunorubicin Approved Phase 3 20830-81-3 30323
40
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
41
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
42
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
43 Reslizumab Approved, Investigational Phase 3,Phase 2
44
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 3 53-03-2 5865
45 Bone Density Conservation Agents Phase 3
46 Calcium, Dietary Phase 3
47 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
48 N-Methylaspartate Phase 3
49 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
2 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
3 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
4 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
5 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
7 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Completed NCT03052725 Phase 3 reslizumab
10 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
11 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
12 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
13 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
14 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
15 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
16 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Recruiting NCT03306043 Phase 3 Mepolizumab
17 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
18 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
19 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
20 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
21 Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Terminated NCT00097370 Phase 3 mepolizumab
22 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
23 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
24 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
25 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
26 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Completed NCT00086658 Phase 2 mepolizumab
27 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
28 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
29 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Completed NCT00483067 Phase 2 2-CdA;Ara-C;G-CSF (Granulocyte colony-stimulating factor)
30 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
31 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
32 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
33 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed NCT00555581 Phase 2 Imatinib Mesylate
34 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
35 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
36 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
37 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
38 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
39 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
40 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
41 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
42 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
43 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Completed NCT02560610 Phase 2 OC000459;Placebo
44 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
45 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
46 Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib Mesylate
47 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
48 Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Recruiting NCT03469934 Phase 2 ANB020;Placebo
49 Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02130882 Phase 2 benralizumab
50 Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02101138 Phase 2 Dexpramipexole

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: eosinophilia

Genetic Tests for Hypereosinophilic Syndrome

Genetic tests related to Hypereosinophilic Syndrome:

# Genetic test Affiliating Genes
1 Eosinophilia 29

Anatomical Context for Hypereosinophilic Syndrome

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

41
T Cells, Skin, Heart, Myeloid, Testes, Lung, Bone

Publications for Hypereosinophilic Syndrome

Articles related to Hypereosinophilic Syndrome:

(show top 50) (show all 1573)
# Title Authors Year
1
Eosinophilic colitis and colonic eosinophilia. ( 30480590 )
2019
2
Paraneoplastic hypereosinophilic syndrome associated with IL3-IgH positive acute lymphoblastic leukemia. ( 30207070 )
2019
3
Peripheral Eosinophilia Found in Pediatric Enterobius vermicularis Infections. ( 30280584 )
2019
4
Prevalence and Clinical Features of Drug Reactions With Eosinophilia and Systemic Symptoms Syndrome Caused by Antituberculosis Drugs: A Retrospective Cohort Study. ( 30479080 )
2019
5
Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood. ( 28986919 )
2018
6
Cardiac involvement in hypereosinophilic syndrome. ( 29922025 )
2018
7
Hypereosinophilic Syndrome Complicated by Eosinophilic Myocarditis With Dramatic Response to Steroid. ( 29581993 )
2018
8
Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. ( 29496465 )
2018
9
Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. ( 29751154 )
2018
10
Bilateral Conjunctival Granulomas in A Young Lady with Hypereosinophilic Syndrome - A Case Report. ( 29771605 )
2018
11
Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome. ( 29924226 )
2018
12
A Case of Pulmonary Hypertension Associated with Idiopathic Hypereosinophilic Syndrome. ( 29794385 )
2018
13
Fatal Outcome of Imatinib in a Patient with Idiopathic Hypereosinophilic Syndrome. ( 29780651 )
2018
14
FIP1L1-PDGFRA fusion-negative hypereosinophilic syndrome with uncommon cardiac involvement responding to imatinib treatment: A case report. ( 29977537 )
2018
15
Eosinophilic Fasciitis in Association With Hypereosinophilic Syndrome in an HIV-Infected Patient With Severe Multiorgan Involvement. ( 29661739 )
2018
16
Hypereosinophilic syndrome presenting acutely with neurologic signs. ( 29501486 )
2018
17
Hypereosinophilic syndrome preceding a diagnosis of B-cell lymphoma. ( 29714651 )
2018
18
Hypereosinophilic Syndrome in the Differential Diagnosis of Pulmonary Infiltrates with Eosinophilia. ( 29803709 )
2018
19
Lymphocytic variant of hypereosinophilic syndrome presenting with polymorphic cutaneous manifestations and nonspecific histopathological findings. ( 29781265 )
2018
20
Lymphocyte-Variant Hypereosinophilic Syndrome With Eosinophilic Myocarditis Treated With Steroids and Pegylated Interferon Alfa-2a. ( 29406050 )
2018
21
IL-5 Levels in Nasosorption and Sputosorption Correlate with Sputum Eosinophilia in Allergic Asthma. ( 30335470 )
2018
22
Nasal eosinophilia in nasal smears of patients with persistent and intermittent allergic rhinitis. ( 30392487 )
2018
23
Role of nasal challenge and local eosinophilia in indirect exposure to cat in allergic rhinitis patients. ( 29479937 )
2018
24
Tumor Associated Tissue Eosinophilia in Ameloblastoma. ( 30361905 )
2018
25
Anaplastic Large Cell Lymphoma Manifesting as Pleural Effusion in a Patient with Long-Standing Eosinophilia. ( 30016448 )
2018
26
Eosinophilia in pediatric uncomplicated appendicitis is a time stable pattern. ( 30535523 )
2018
27
Phlegmonous appendicitis in children is characterized by eosinophilia in white blood cell counts. ( 30043224 )
2018
28
Correction to: Phlegmonous appendicitis in children is characterized by eosinophilia in white blood cell counts. ( 30242781 )
2018
29
Persistent eosinophilia in rheumatoid arthritis: a prospective observational study. ( 30426234 )
2018
30
Epithelial SERPINB10, a novel marker of airway eosinophilia in asthma, contributes to allergic airway inflammation. ( 30382768 )
2018
31
The characterization of asthma with blood eosinophilia in adults in Latin America. ( 30395744 )
2018
32
Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma. ( 30342585 )
2018
33
Quantitative Analysis of Tumor-associated Tissue Eosinophilia in Recurring Bladder Cancer. ( 30443450 )
2018
34
Is peripheral eosinophilia associated with the different morphological characteristics of bullous pemphigoid? ( 30387513 )
2018
35
Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature. ( 29309291 )
2018
36
Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. ( 29663327 )
2018
37
A 56-Year-Old Man With Cardiac Tamponade and Eosinophilia. ( 30526985 )
2018
38
Case report of hypereosinophilic syndrome presenting as severe ischaemic colitis. ( 30277302 )
2018
39
Disseminated Cryptococcosis with Marked Eosinophilia in a Postpartum Woman. ( 29021482 )
2018
40
Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization management. ( 30096127 )
2018
41
A familial mediterranean fever flare induced by a drug reaction with eosinophilia and systemic symptoms. ( 28653374 )
2018
42
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. ( 29133221 )
2018
43
Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome. ( 29150836 )
2018
44
Clinical, Viral and Genetic Characteristics of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China. ( 29242946 )
2018
45
Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. ( 29265576 )
2018
46
Use of antiviral medications in drug reaction with eosinophilia and systemic symptoms (DRESS): A case of infantile DRESS. ( 29334124 )
2018
47
Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection. ( 29367368 )
2018
48
Paediatric case series of drug reaction with eosinophilia and systemic symptoms (DRESS): 12-year experience at a single referral centre in Hong Kong and the first reported use of infliximab. ( 29384118 )
2018
49
Drug Reaction with Eosinophilia and Systemic Symptoms Associated with Reactivation of Epstein-Barr Virus and/or Cytomegalovirus Leading to Hemophagocytic Syndrome in One of Two Patients. ( 29386835 )
2018
50
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: Case report of severe multiorgan involvement to perindopril/amlodipine combination antihypertensive. ( 29387775 )
2018

Variations for Hypereosinophilic Syndrome

Expression for Hypereosinophilic Syndrome

Search GEO for disease gene expression data for Hypereosinophilic Syndrome.

Pathways for Hypereosinophilic Syndrome

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 ABL1 CCL11 CSF2 EPX FGFR1 IFNA1
2
Show member pathways
13.89 ABL1 CCL11 CCL17 CSF2 FGFR1 IL13
3
Show member pathways
13.71 CCL11 CCL17 CSF2 FGFR1 IFNA1 IL13
4
Show member pathways
13.58 CCL11 CCL17 FGFR1 IFNA1 IL13 IL2RA
5
Show member pathways
13.53 ABL1 CSF2 FGFR1 IL2RA IL3 IL5
6
Show member pathways
13.42 CCL11 CCL17 CSF2 FGFR1 IL13 IL2RA
7
Show member pathways
13.29 CCL11 CSF2 FGFR1 IFNA1 IGHE IL13
8
Show member pathways
13.28 CCL11 CCL17 CSF2 FGFR1 IL13 IL2RA
9
Show member pathways
13.1 FGFR1 IL2RA IL3 KIT PDGFRA PDGFRB
10
Show member pathways
13.09 FGFR1 IL2RA IL3 IL4 KIT PDGFRA
11
Show member pathways
13.07 FGFR1 IFNA1 IL2RA IL3 IL4 KIT
12
Show member pathways
12.93 ABL1 CSF2 FGFR1 IL3 KIT PDGFRA
13 12.78 ABL1 FGFR1 IFNA1 IL13 IL2RA IL3
14
Show member pathways
12.74 ABL1 FGFR1 KIT PDGFRA PDGFRB
15
Show member pathways
12.67 ABL1 CCL11 EPX IFNA1 IL13 IL2RA
16
Show member pathways
12.65 CSF2 IGHE IL13 IL3 IL4 IL5
17 12.6 IFNA1 IL2RA IL3 IL4 KIT
18
Show member pathways
12.53 FGFR1 IL13 IL2RA IL5 PDGFRA PDGFRB
19
Show member pathways
12.49 CSF2 IFNA1 IL3 IL4
20
Show member pathways
12.43 CCL11 CCL17 CSF2 IL13 IL4 IL5
21 12.42 CSF2 IL2RA PDGFRA PDGFRB
22
Show member pathways
12.4 FGFR1 IL3 KIT PDGFRA PDGFRB
23
Show member pathways
12.32 ABL1 CSF2 IFNA1 IL13 IL2RA IL3
24
Show member pathways
12.2 FGFR1 IL2RA PDGFRA PDGFRB
25 12.2 ABL1 FGFR1 KIT PDGFRA PDGFRB
26
Show member pathways
12.18 CSF2 IL2RA IL3 IL5
27 12.16 FGFR1 IL2RA PDGFRA PDGFRB
28
Show member pathways
12.15 CCL11 CCL17 FGFR1 IL13 IL2RA IL3
29 12.09 CSF2 IL2RA IL3 IL4 IL5 KIT
30 12.03 CCL11 IGHE IL13 IL4
31 11.99 CSF2 IL2RA IL3 IL4 IL5 KIT
32 11.93 ABL1 IFNA1 IL2RA IL3
33 11.91 IL13 IL2RA IL4 IL5 KIT
34
Show member pathways
11.88 CSF2 IL2RA IL3 IL4 IL5
35 11.87 CSF2 IL13 IL4 IL5
36 11.85 CCL11 CCL17 CSF2 IL13 IL4
37 11.84 FGFR1 PDGFRA PDGFRB
38
Show member pathways
11.84 ABL1 KIT PDGFRA PDGFRB
39
Show member pathways
11.8 FGFR1 KIT PDGFRB
40 11.79 CCL11 CCL17 IGHE IL4 IL5
41 11.78 CCL11 CSF2 IL13 IL4 IL5
42 11.76 FGFR1 KIT PDGFRA PDGFRB
43
Show member pathways
11.57 ABL1 FGFR1 IFNA1 IL13 IL2RA IL3
44 11.56 CSF2 IL13 IL4
45 11.55 CSF2 IL3 IL5
46 11.54 CCL11 CCL17 IL13 IL2RA IL4 IL5
47 11.52 FGFR1 PDGFRA PDGFRB
48 11.49 FGFR1 PDGFRA PDGFRB
49 11.37 IL2RA IL4 IL5
50 11.36 IL13 IL4 IL5

GO Terms for Hypereosinophilic Syndrome

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL11 CCL17 CSF2 EPX IFNA1 IL13
2 receptor complex GO:0043235 9.56 FGFR1 KIT PDGFRA PDGFRB
3 external side of plasma membrane GO:0009897 9.55 IGHE IL13 IL2RA KIT PDGFRA
4 extracellular region GO:0005576 9.44 CCL11 CCL17 CSF2 EPX FGFR1 IFNA1

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.96 EPX IGHE PRG2 RNASE3
2 positive regulation of cell migration GO:0030335 9.96 CCL11 KIT PDGFRA PDGFRB
3 regulation of cell proliferation GO:0042127 9.94 ABL1 CSF2 FGFR1 KIT
4 positive regulation of protein kinase B signaling GO:0051897 9.93 FGFR1 KIT PDGFRA PDGFRB
5 chemotaxis GO:0006935 9.92 CCL11 CCL17 PDGFRA PDGFRB
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 ABL1 CCL11 CCL17 FGFR1 KIT PDGFRA
7 positive regulation of MAPK cascade GO:0043410 9.89 FGFR1 KIT PDGFRA PDGFRB
8 protein autophosphorylation GO:0046777 9.88 ABL1 FGFR1 KIT PDGFRA PDGFRB
9 MAPK cascade GO:0000165 9.86 CSF2 FGFR1 IL2RA IL3 IL5 KIT
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 KIT PDGFRA PDGFRB
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 ABL1 IL3 IL5
12 cell chemotaxis GO:0060326 9.85 KIT PDGFRA PDGFRB
13 negative regulation of signal transduction GO:0009968 9.85 FGFR1 KIT PDGFRA PDGFRB
14 immune response GO:0006955 9.85 CCL11 CCL17 CSF2 IGHE IL13 IL2RA
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 CSF2 IL13 IL3 IL4 KIT
16 positive regulation of MAP kinase activity GO:0043406 9.82 FGFR1 KIT PDGFRB
17 phosphatidylinositol phosphorylation GO:0046854 9.81 FGFR1 KIT PDGFRA PDGFRB
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 FGFR1 KIT PDGFRA PDGFRB
19 phosphatidylinositol-mediated signaling GO:0048015 9.79 FGFR1 PDGFRA PDGFRB
20 positive regulation of B cell proliferation GO:0030890 9.77 IL13 IL4 IL5
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.76 ABL1 IL13 IL4
22 platelet-derived growth factor receptor signaling pathway GO:0048008 9.71 ABL1 PDGFRA PDGFRB
23 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.7 KIT PDGFRA PDGFRB
24 embryonic hemopoiesis GO:0035162 9.68 IL3 KIT
25 dendritic cell differentiation GO:0097028 9.67 CSF2 IL4
26 positive regulation of podosome assembly GO:0071803 9.67 CSF2 IL5
27 response to fluid shear stress GO:0034405 9.65 CSF2 PDGFRB
28 retina vasculature development in camera-type eye GO:0061298 9.65 PDGFRA PDGFRB
29 mast cell chemotaxis GO:0002551 9.62 CCL11 KIT
30 positive regulation of phospholipase C activity GO:0010863 9.62 FGFR1 KIT PDGFRA PDGFRB
31 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.61 ABL1 PDGFRB
32 metanephric glomerular capillary formation GO:0072277 9.58 PDGFRA PDGFRB
33 negative regulation of complement-dependent cytotoxicity GO:1903660 9.57 IL13 IL4
34 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.56 PDGFRA PDGFRB
35 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
36 cytokine-mediated signaling pathway GO:0019221 9.32 CCL11 CSF2 IFNA1 IGHE IL13 IL2RA
37 protein phosphorylation GO:0006468 10.1 ABL1 CCL11 FGFR1 KIT PDGFRA PDGFRB
38 negative regulation of apoptotic process GO:0043066 10.08 FGFR1 IL4 KIT PDGFRA PDGFRB
39 inflammatory response GO:0006954 10.04 CCL11 CCL17 IL13 IL5 KIT
40 regulation of signaling receptor activity GO:0010469 10.01 CCL11 CCL17 CSF2 IFNA1 IL13 IL3
41 positive regulation of cell proliferation GO:0008284 10 CSF2 FGFR1 IL3 IL5 KIT PDGFRA

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.89 ABL1 FGFR1 KIT PDGFRA PDGFRB
2 transmembrane signaling receptor activity GO:0004888 9.76 FGFR1 KIT PDGFRA PDGFRB
3 cytokine activity GO:0005125 9.76 CCL11 CCL17 CSF2 IFNA1 IL13 IL3
4 growth factor activity GO:0008083 9.73 CSF2 IL3 IL4 IL5
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 FGFR1 KIT PDGFRA PDGFRB
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 FGFR1 KIT PDGFRA PDGFRB
7 protein tyrosine kinase activity GO:0004713 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
8 cytokine receptor binding GO:0005126 9.54 IFNA1 IL13 IL4
9 platelet-derived growth factor receptor binding GO:0005161 9.51 PDGFRA PDGFRB
10 platelet-derived growth factor binding GO:0048407 9.48 PDGFRA PDGFRB
11 vascular endothelial growth factor binding GO:0038085 9.4 PDGFRA PDGFRB
12 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 CSF2 FGFR1 IL2RA IL3 IL5 KIT

Sources for Hypereosinophilic Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....